Stockreport

Merck refiles U.S. application for six-week dosing for Keytruda [Seeking Alpha]

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF Merck (NYSE:MRKThe company received aComplete Response LetteCurrently, the PD-1 inhibitor is administered at 200 mg infused over 30 minutes every three weeks.Shares down [Read more]